Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Could Gilead Make A Profit From Remdesivir?

Roche’s Tamiflu Was A Pandemic Blockbuster, But COVID-19 Is Different

Apr 23 2020

• By Andrew McConaghie

Gilead_USA

Related Content

Remdesivir Shows Promising Results In Leaked Report But Doubts Remain

Apr 17 2020

Apparent China Study Failure May Not Spell End For Remdesivir COVID-19 Role

Apr 24 2020

Coronavirus Update: Gilead Says 'Inappropriate Characterizations' In Remdesivir Trial Flop Leak

Apr 24 2020

Gilead Calls Forty Seven Buyout Complementary To Kite, Other IO Efforts

Mar 02 2020

Related Companies

Gilead Sciences, Inc.

Additional Topics

Coronavirus COVID-19 Market Access Pricing Debate BioPharmaceutical

More from COVID-19

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window